NRx Pharmaceuticals (NASDAQ:NRXP) Stock Rating Lowered by Wall Street Zen

NRx Pharmaceuticals (NASDAQ:NRXP) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Other equities research analysts have also recently issued research reports about the company. D. Boral Capital reissued a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Friday, May 8th. Zacks Research raised NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. BTIG Research reissued a “buy” rating and issued a $25.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th. Finally, Ascendiant Capital Markets raised their price objective on NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.25.

NRx Pharmaceuticals Stock Performance

Shares of NRx Pharmaceuticals stock opened at $4.14 on Friday. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05. The stock has a 50 day moving average price of $3.01 and a two-hundred day moving average price of $2.43. The stock has a market capitalization of $149.99 million, a PE ratio of -3.80 and a beta of 2.14.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $19.43 million. Research analysts forecast that NRx Pharmaceuticals will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Sjbenen Advisory LLC purchased a new position in shares of NRx Pharmaceuticals during the fourth quarter valued at approximately $41,000. Ethos Financial Group LLC boosted its position in shares of NRx Pharmaceuticals by 33.6% during the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after buying an additional 4,000 shares during the last quarter. One Wealth Management Investment & Advisory Services LLC boosted its position in shares of NRx Pharmaceuticals by 35.3% during the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock valued at $103,000 after buying an additional 9,882 shares during the last quarter. Global Retirement Partners LLC purchased a new position in shares of NRx Pharmaceuticals during the fourth quarter valued at approximately $107,000. Finally, Two Sigma Investments LP boosted its position in shares of NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after buying an additional 20,880 shares during the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.